Targeted Antibodies for Cancer 2011
In recent years, targeted antibodies have emerged as playing a pivotal role in cancer therapeutics and are an important area for the pharmaceutical, biotech and medical industries.
In such a fast-paced and competitive field, it is crucial for the key players to stay up-to date with the recent advances in antibody research and development.
TAC2011 will address the critical scientific issues and challenges associated with developing targeted therapeutic antibodies for cancer. It will highlight improvements in antibody development, global trends and current clinical progress.